Meaningful improvements in physical function and disability due to joint pain occur promptly and are durable through at least three years of follow-up.
In a population of subjects with subclinical hypothyroidism, a thyroid stimulating hormone > 6.35 mIU/L was the threshold for increasing mortality risk.
Financial Disclosure: To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, Dr. Brunton (editor) reports he is a retained consultant for Abbott, Actavis, AstraZeneca, Becton Dickinson, Boehringer Ingelheim, Cempra, Exact Sciences, Janssen, Lilly, Mylan, Novo Nordisk, and Teva; and he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, and Teva. Dr. Kuritzky (author) reports he is a retained advisor/consultant for AbbVie, Allergan, AstraZeneca, Janssen, Lilly, Lundbeck, Medscape, Novo Nordisk, and Sanofi Aventis, and serves on the speakers bureau of Lilly and Lundbeck. Ms. Coplin (executive editor), and Mr. Springston (associate managing editor) report no financial relationships relevant to this field of study.
